Tickerplace logo

Tickerplace

Inhibikase Therapeutics, Inc. logo

IKTInhibikase Therapeutics, Inc.

IKT Stock Price, Valuation & Chart | Inhibikase Therapeutics, Inc.

Compare
$2.500+0.12 (+5.04%)

At close · 02 Sept 2026, 08:00 pm

Sector: HealthcareIndustry: BiotechnologyIKT intrinsic valueIKT calculated fair value vs price
OverviewFinancialsDividendsRatios

IKT Historical price chart

IKT Key Stats

Fair Value
Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock
Market Capitalization330.08M
PE Ratio-5.81
EPS-0.43
Trading Volume378.89K
Today's High/Low2.54/2.39
Dividend Yield0.00
52 Week High/Low2.54/1.33
Shares Outstanding132.03M
IKT Financial Statement
IKT Analyst ratings
IKT Analysis & performance metrics

IKT Company profile

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside…

IKT Management team

Management
Jeffrey J. Kagy
Chief Human Resources Officer
Mark T. IwickiCEO
Chief Executive Officer & Director
John Adams Ph.D.
Chief Scientific Officer
Christopher H. Cabell FACC, M.D.
President, Head of Research & Development and Chief Medical Officer
David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A.CFO
Chief Financial Officer
Chadwick J. Orevillo MPH
Executive Vice President & Head of Development Operations
Total 6 executives

IKT Frequently asked questions

What is Inhibikase Therapeutics, Inc. (IKT) Stock Price?

Current stock price of Inhibikase Therapeutics, Inc. (IKT) stock is $2.500. The stock price is +5.04% higher in the session. The intraday range can be seen from this page. Volume of Inhibikase Therapeutics, Inc. (IKT) stock is 378.89K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Inhibikase Therapeutics, Inc. (IKT) stock price going up or down today?

The stock price of Inhibikase Therapeutics, Inc. (IKT) can change with earnings, company news, and overall market sentiment. Inhibikase Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Inhibikase Therapeutics, Inc. stock expensive at its current price?

Whether Inhibikase Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IKT on this page is -5.81. EPS on this page is -0.43. Compare those figures with peers and growth expectations before deciding if the current Inhibikase Therapeutics, Inc. price is justified.

How has the stock price of Inhibikase Therapeutics, Inc. (IKT) performed historically?

Historical performance for Inhibikase Therapeutics, Inc. (IKT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IKT reacted to past earnings and market events.

Should I buy Inhibikase Therapeutics, Inc. (IKT) stock, at this price?

Buying Inhibikase Therapeutics, Inc. (IKT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.